PA5-103744

antibody from Invitrogen Antibodies

Targeting: CMTM7 CKLFSF7, FLJ30992

Western blot (Data presented on provider website)

Immunohistochemistry (Recommended by provider)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-103744

Provider

Invitrogen Antibodies

Product name

CMTM7 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

Antibody detects endogenous levels of total CKLF7.

Reactivity

Human, Mouse

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

1 mg/mL

Storage

-20°C

References

Submitted references

Breast cancer cell-derived extracellular vesicles transfer miR-182-5p and promote breast carcinogenesis via the CMTM7/EGFR/AKT axis.

Lu C, Zhao Y, Wang J, Shi W, Dong F, Xin Y, Zhao X, Liu C
Molecular medicine (Cambridge, Mass.) 2021 Jul 16;27(1):78

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 6 EVs-miR-182-5p induces proliferation, migration and angiogenesis of HUVECs through inhibition of CMTM7 and activation of the EGFR/AKT signaling pathway. A Venn diagram of genes related to CMTM7 expression in breast cancer tissue samples from dataset GSE50428, MEM database and LinkedOmics database; B PPI network of 98 intersection genes related to CMTM7 expression constructed using String (in the PPI network, the higher core degree is, the more red the circle color is; otherwise, the lower the core degree, the bluer the color is); C Expression of CMTM7, VEGF, p-EGFR, EGFR, p-AKT and AKT in HUVECs treated with EVs or combined with miR-182-5p inhibitor by Western blot analysis, the statistical power was 1; D Expression of CMTM7, VEGF, p-EGFR, EGFR, p-AKT and AKT in HUVECs treated with EVs or combined with GDC0068 detected by Western blot analysis, the statistical power was 1; E Proliferation of HUVECs treated with EVs or combined with GDC0068 detected by CCK-8 method, the statistical power was 1; F Migration of HUVECs treated with EVs or combined with GDC0068 detected by scratch test, the statistical power was 1; G Migration ability of HUVECs treated with EVs or combined with GDC0068 detected by Transwell assay, the statistical power was 1; H Vessel-like tube formation in vitro of HUVECs treated with EVs or combined with GDC0068, the statistical power was 1. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared with control HUVECs, or HUVECs treated with PBS or

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 7 EVs-miR-182-5p exerts promoting effect on tumorigenesis and metastasis of breast cancer cells in vivo by the CMTM7/EGFR/AKT axis. Mice were treated with EVs + inhibitor NC, EVs + miR-182-5p inhibitor, or EVs + miR-182-5p inhibitor + si-CMTM7. A Tumor volume of nude mice, the statistical power was 1; B Tumor weight of nude mice after 28 days of modeling, the statistical power was 1; C Expression of miR-182-5p in tumor tissues of nude mice detected by RT-qPCR, the statistical power was 1; D Expression of CMTM7, p-EGFR, EGFR, VEGF, p-AKT and AKT protein in tumor tissues of nude mice detected by Western blot analysis, the statistical power was 1; E - F Number E and size ( F ) of pulmonary metastasis in nude mice, the statistical power was 1; G - H CD31 ( G ) and Ki-67 ( H ) immunohistochemical staining of pulmonary metastasis tissues in nude mice, the statistical power was 1. N = 10 for mice following each treatment. **** p < 0.0001 compared with mice treated with EVs + inhibitor NC. #### p < 0.0001 compared with HUVECs treated with EVs + miR-182-5p inhibitor + si-NC. The experiment was conducted three times independently

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Additional file 3: Fig. S2. CMTM1 exerts suppressed HUVECs proliferation, migration and angiogenesis. HUVECs were treated with oe-CMTM7 or EVs or EVs + oe-CMTM7. The mRNA (A) and protein (B) expression of CMTM7 detected by RT-qPCR and Western blot analysis, respectively. The statistical power was 1; (C) The proliferation of HUVECs detected by CCK-8 assay, the statistical power was 1; (D) Migration ability of HUVECs detected by scratch test, the statistical power was 1; (E) Migration ability of HUVECs detected by Transwell assay, the statistical power was 1; (F) Vessel-like tube formation in vitro of HUVEC, the statistical power was 1. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 compared with HUVEC; # p < 0.05, ## p < 0.01, ### p < 0.001, #### p < 0.001compared with HUVEC treated with EVs. The experiment was conducted three times independently.